Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.6K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.6K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

14.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.3K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.6K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.8K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.8K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

8.2K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Related Experiment Video

Updated: Dec 13, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K

Mantle cell lymphoma.

Sergio Cortelazzo1, Maurilio Ponzoni2, Andrés J M Ferreri3

  • 1Oncology Unit, Humanitas/Gavazzeni Clinic, Bergamo, Italy.

Critical Reviews in Oncology/Hematology
|August 3, 2020
PubMed
Summary
This summary is machine-generated.

Mantle cell lymphoma (MCL) management is evolving, with new subtypes and treatments like rituximab showing promise. Clinical trials are crucial for identifying optimal strategies and improving patient survival outcomes.

Keywords:
Classical and indolent MCLMRD monitoringMaintenanceTargeted therapies

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

663
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.6K

Related Experiment Videos

Last Updated: Dec 13, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.5K
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

663
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.6K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Mantle cell lymphoma (MCL) is typically aggressive with a poor prognosis, though indolent forms exist.
  • The 2017 WHO classification distinguished classical and indolent leukaemic nonnodal MCL subtypes.
  • Recent advances suggest improving outcomes for MCL patients.

Purpose of the Study:

  • To review current understanding and treatment strategies for Mantle Cell Lymphoma.
  • To highlight the impact of new classifications and therapeutic additions like rituximab.
  • To discuss the evolving landscape of MCL management, including targeted therapies and stem cell transplantation.

Main Methods:

  • Review of recent research findings and clinical trial results in MCL.
  • Analysis of the efficacy of conventional chemotherapy combined with rituximab.
  • Evaluation of intensive frontline therapies, including autologous stem cell transplantation.
  • Consideration of alternative regimens for non-eligible patients and allogeneic SCT for relapsed disease.

Main Results:

  • Rituximab improved response rates but not overall survival when added to chemotherapy.
  • Intensive therapies with rituximab and autologous stem cell transplantation improved progression-free survival in young patients, with survival impact unproven.
  • Optimal timing, regimens, and implications of molecular remission require further elucidation.
  • Targeted therapies hold potential to improve outcomes and reduce toxicity.

Conclusions:

  • MCL management is evolving, with distinct subtypes and treatment responses.
  • While progress has been made, overall survival benefits from intensive therapies remain to be definitively proven.
  • Enrollment in clinical trials is essential for advancing MCL treatment strategies and identifying optimal patient management approaches.